Skip to main content
PLOS One logoLink to PLOS One
. 2022 Nov 2;17(11):e0276857. doi: 10.1371/journal.pone.0276857

Predictors of unwillingness to receive COVID -19 vaccines among Ethiopian Medical students

Dawit Getachew 1,*, Tewodros Yosef 1, Nahom Solomon 1, Melkamsew Tesfaye 1, Eyob Bekele 2
Editor: Dragan Pamucar3
PMCID: PMC9629586  PMID: 36322591

Abstract

Introduction

Medical students are among the potential risky population for the transmission of COVID 19 infections; their willingness to receive COVID 19 vaccine is not well studied. Thus, this study assessed Predictors of Unwillingness to receive COVID -19 vaccines among Ethiopian Medical students.

Methods

From the 25th of May, 2020 to the 26th of June, 2021, an institution-based cross-sectional study was done at Mizan-Tepi University Teaching Hospital,On 313 medical students from each department and batch were chosen using a multistage sampling approach. A bivariate and multivariable logistic regression were done to identify the predictors of Unwillingness to receive COVID -19 vaccines. Figures, tables, and graphs were used to present the findings. The adjusted odds ratio and its 95% confidence interval were provided.

Results

In this study 124 (40.7%) 95% CI (35.1,46.4) medical students were not willing to receive the COVID-19 vaccine. And also increased in the age of the student[AOR 0.43, 95% CI; (.29,.63)], Knowledge status about COVID 19 infection transmission, risk factors and control behavior[AOR 1.45, 95% CI; (1.14, 1.85)], perceived susceptibility to COVID 19 infection [AOR 1.70 (1.15, 2.51)], perceived severity of COVID 19 infection[AOR 1.26 (1.01, 1.57)], perceived benefit of COVID 19 vaccine [AOR .58(.38, .88)], positive attitude towards COVID 19 vaccines [AOR .46(.35, .62)], and confidence in safety and efficacy of the vaccine and public authorities decissin in the best interest of the community [AOR 1.93(1.24, 2.99)] were predictors of non-willingness to receive COVID 19 vaccine.

Conclusion

Non-willingness to accept the COVID 19 vaccine was predicted by student age, elements in the Health belief model such as anticipated susceptibility, severity, and benefit, and a positive attitude and trust in the vaccine.

Introduction

Since the start of the COVID 19 pandemic, there have been 249,523,057 cases reported, of whom 5,048,656 have died and 225,965,382 have recovered; according to this report, 366,424 persons have been infected and 6,509 have died [1]. To fight the pandemic several strategies were developed and implemented; vaccination was the most trusted one. In combination with respiratory and personal hygiene and social distancing, COVID 19 vaccination is a promising strategy to tackle the COVID 19 pandemic.

To date, there are around 8 registered vaccines by WHO. The developments of COVID-19 vaccines were similar to all medicine; first, the vaccines were tested in a laboratory, then on human volunteers [2]. However, high COVID-19 Vaccine Hesitancy is becoming a great concern [3]. Vaccine hesitancy refers to delay in acceptance or refusal of vaccines; It is global problem increasingly being recognized which is common in new or newly introduced vaccines and it differs in a different context [4].

In a study done in South Carolina, About 26.1% of students reported they would take COVID-19 vaccines when available [5]. In the USA Almost half of the college students (47.5%) participants reported hesitancy to receive the COVID-19 vaccine [6]. In a Medical University in Riyadh, Saudi Arabia only 66% accepted the vaccine [7]. Medical students frequently rotate between hospital sites and general practice during their clinical placement years and can potentially be a hidden reservoir for COVID-19 [8]. Among medical students in Kazakhstan, Only 2% were vaccinated and 22.4% showed the potential for COVID-19 vaccine acceptance [9]. In India, Vaccine hesitancy was found among 10.6% of the medical and dental students [10]. In Egypt, 46% of medical students had vaccination hesitancy [11, 12].

In Ethiopia, the willingness to receive COVID 19 vaccine among the general population group was reported to be low; only 31.4% were willing to take the COVID-19 vaccine [13]. In Wolaita Sodo town 46.1% willingness to take a COVID-19 vaccine [14].

The majority of non-medical students showed hesitancy towards obtaining COVID-19 vaccines compared to medical students who were more willing, largely owing to their knowledge and understanding of vaccines [15]. In Uganda COVID-19 vaccine acceptability among medical students was 37.3% and vaccine hesitancy was 30.7% [16]. The reasons for hesitancy were different in a different study [17].

Most University students reported their reasons for receiving the COVID-19 vaccine included preventive purposes, a belief in the safety of the vaccines, and the availability of public awareness information regarding the vaccines [18]. In Saudi Arabia, only 66% percent of r participants had taken the vaccine [19]. The most confirmed barriers to COVID-19 vaccination were deficient data regarding the potential and unknown vaccine’s adverse effects and insufficient information regarding the vaccine itself [11].

Varied populations and the same population group with various background information have different COVID 19 vaccination predictions. For example, no demographic characteristics were statistically connected with the COVID-19 vaccine’s acceptance [18]. However, in another study, being a male and single medical student was linked to vaccine acceptability [16] the field of education [20], year of education [21]. In addition to this, Perceived risk of getting COVID 19 in the future, and receiving any vaccine in the past 5 years [16]. Not only this Acceptability of the COVID-19 vaccine was strongly associated getting regularly received the flu vaccine [18].

Despite the fact that the pandemic has affected people from many walks of life, medical students are particularly vulnerable because to their housing situation, workplace conditions, and the difficulties of implementing a preventive strategy while on clinical and community attachments. Furthermore, no previous research on this topic has been conducted in Ethiopia. As a result, the Predictors of Unwillingness to Receive COVID-19 Vaccines among Ethiopian Medical Students were studied in this study.

Material and methods

Study area and period

The study was conducted at Mizan Tepi University Teaching Hospital from the 25th of May, 2020 to the 26th of June, 2021. The University is found in the Southwest of Ethiopia, Mizan Aman City, 590 km away from the capital city of Ethiopia.

Study design

An Institutional based cross-sectional study was done.

Population

Source population and study population

The source populations were all regular Medical students attending Mizan Tepi University in the 2020/2021 academic year. The study populations were all selected regular Medical students attending Mizan Tepi University in the 2020/2021 academic year.

Inclusion criteria and exclusion criteria

All medical students attending Mizan Tepi University in the 2020/2021 academic year during the data collection period were included. Medical students who were critically ill and unable to respond during data collection were excluded.

Sample size determination and sampling technique

The sample size was calculated using single proportion formula in EPI Info software; with the following assumption Proportion of willingness tno accept COVID 19 vaccines as 50%, Margin of error of 5%, and Zα/2 95 CL = 1.96 and total number source population 1100. After adjusting for the small source population and potential non-response rate of 10%, the final sample was 313.

n = (Z2)2P1-Pd2

The total sample size was proportionally allocated to each batch of the six departments namly Public health, Medicine, Nursing, Pharmacy, Medical lab and Midwifery; to select study participants randomly (Fig 1).

Fig 1. Sampling distribution flow chart.

Fig 1

Data collection methods and materials

The data were collected using a pretested, self-administered questionnaire, which was adapted from previous literature [11, 2224] and was prepared in the English language. The questionnaire has four parts; Part 1 asks about the personal identification information of the student, which includes the age, gender, department, year of the student, and Exposure to COVID-19 infection. Part 2: Knowledge about transmission, risk factors, and preventive behavior of COVID-19 Infection. Part: 3 Items used to measure HBM, The TPB, and The 5C Psychological Antecedents of Vaccination. Part 4; measures the willingness to receive the COVID 19 vaccine [24] and perceived barriers and motivators of COVID-19.

Data processing and analysis

The data was entered into Epi-Data version 4.2.0 and exported to SPSS version 21 software packages. Descriptive analysis results were presented in the form of tables, figures, frequencies, and summary statistics. The variable which was significant at a p-value less than 0.25 in the bivariate logistic regression analysis was entered into multiple logistic regression, and the variable which has P-value <0.05 was considered a statistically significant predictor.

Ethics approval and consent to participate

This study was conducted in harmony with the Declaration of Helsinki. Mizan Tepi University Research Ethics Review Committee approved it. All participant were assured the autonomy to participate or not, the a written informed consent was sought from each participant.

Result

In this study, the response rate is 97.44% as 305 out of 313 samples completed in the interview.

Personal identification information of the study participants

The mean age of the medical students who participated in this study was 23.22, with a standard deviation of 2.62 and 192. Additionally, 189 of them were men (63%) and 223 (73.1%) of them were from rural areas of the country. In terms of their field, 68 (22.3%) of the students were in public health, 19 (6.2%) in medicine, 43 (14.1%) in pharmacy, 75 (24.6%) were nurses, 37 (12.1%) were in the laboratory, and 60 (20.3%) were midwives. In addition, 22(7.2%) of them have one or more chronic illnesses (Table 1).

Table 1. Socio-demographic characteristics of study participants.

Variable Category Frequency n (%)
Gender Male 189(62.0)
Female 116 (38.0)
Religion Orthodox 160(52.5)
Protestant 47(15.4)
Muslim 98(32.1)
Place of origin Urban 81(6.9)
Rural 223(73.1)
Department Public health 68 (22.3)
Medicine 19 (6.2)
Pharmacy 43 (14.1)
Nurse 75 (24.6)
Medical Laboratory 37 (12.1)
Midwife 63 (20.7)
Academic Year 1st year 34 (11.1)
2nd Year 54 (17.7)
3rd Year 63 (20.7)
4th Year 72 (23.6)
5th year 94 (30.)
Chronic illness Yes 22 (7.2)
No 283 (92.8)

Knowledge about transmission, risk factors, and preventive behavior of COVID-19

The mean score for the overall knowledge about transmission, risk factors, and preventive behavior of COVID-19 was 23.35± 3.86 SD (mean score for Knowledge about COVID-19 transmission was 8.69, ± 2 SD, mean score for Knowledge about COVID-19 risk factors was 6.61 ± 1.80 SD and mean score for Knowledge about COVID-19 Preventive behavior was 8.05 ± 1.07 SD). The overall knowledge level was categorized by taking the mean as the cut of point. Hence, 207(67.9%) of medical student participated in this study have good knowledge about transmission, risk factors, and preventive behavior of COVID-19.

Willingness to receive COVID-19 vaccine among medical students

In this study, the mean score of willingness to take COVID-19 vaccine among medical student was 8.56 with a 95% CI (8.44, 9.23). When willingness to take COVID-19 vaccine is dichotomized as below the mean and above the mean, the overall willingness to take the COVID-19 vaccination is 181 (59.3%), while the overall unwillingness to receive the COVID-19 vaccine is 124 (40.7%) with the 95% CI (35.1,46.4).Only 31 (12.1%) of respondents, strongly agreed that they were intended to receive a COVID-19 vaccine, and 22 (8.6%) of respondents highly predicted that they would receive a COVID-19 vaccine in the near future. Likewise, 22 (8.6%) of respondents planned to receive a COVID-19 vaccine (Fig 2).

Fig 2. Willingness to receive vaccine against COVID-19 among medical student.

Fig 2

Reason for unwillingness to receive COVID 19 vaccine among participants

Medical student who were participated in this study but unwilling to get the COVID 19 vaccine have mentioned the following reasons: vaccine’s effectiveness is questioned 60(30.2%), concerned about the vaccine’s minimal adverse effects (e.g., fever, pain at the injection site) 59(29.6), would want to gain more experience 37 (18.6%), I am not afraid of becoming infected with COVID-19.17(8.5%), I am afraid of significant vaccination side effects (e.g., hospitalization, serious illness)15 (7.5%), I am not at risk of serious COVID-19 virus infection 11 (5.5%) (Fig 3).

Fig 3. Reason for none willingness to receive COVID 19 vaccine among medical student.

Fig 3

Predictors of unwillingness to receive Covid-19 vaccine among medical students

Regarding the factors that affect medical students’ willingness to receive COVID 19 vaccine, multivariate analysis showed that only the students’ age were significantly associated with their willingness to do so. perceived susceptibility to COVID 19 infection, perceived severity of COVID 19 infection and perceived benefit of COVID 19 vaccine significantly predicted non-willingness to obtain COVID 19 vaccine from the HBM variables, whereas perceived COVID 19 vaccine barriers did not. Additionally, only attitude toward the COVID 19 vaccine was a significant predictor of non-willingness to get the COVID 19 vaccine among the components from the Theory of Planned Behavior. Finally, only confidence has shown a significant association with refusal to take the COVID 19 vaccine among the five C variables.

In this study, for one year increase in the age of medical student, the odds of unwillingness to receive COVID 19 vaccines decreased by 57%, [AOR 0.43, 95% CI; (.29,.63)]. And also, the odds of non-willingness to accept COVID 19 vaccine was 1.45 times higher among medical student who have a high score of knowledge as compared to their counter part [AOR 1.45, 95% CI; (1.14, 1.85)]. In addition to this, from the HBM factors perceived susceptibility to COVID 19 infection was 1.70 (1.15, 2.51), perceived severity of COVID 19 infection was 1.26 (1.01, 1.57), and perceived benefit of COVID 19 vaccine was .58(.38, .88) were significantly predicted non-willingness to receive COVID 19 vaccine; while perceived barriers of COVID 19 vaccine were not predicted it. Moreover, from the Theory of planned behavior factors, only attitude towards COVID 19 vaccine was significantly associated with non-willingness to receive COVID 19 vaccine .46(.35, .62). Finally from the 5 C factors, only confidence has shown a statistical association with non-willingness to receive COVID 19 vaccine 1.93(1.24, 2.99). (Table 2).

Table 2. Determinants of willingness to receive COVID-19 among medical students in Mizan Tepi University, Ethiopia, 2021.

Variable Willingness COR, 95%CI COR, 95%CI
Personal identification, self-reported health status
Gender Male 79(63.7) 110(60.8) 1
Female 45(36.3) 71(39.2) 1.13(.71, 1.82)
Age (μ±SD) 23.60±2.79 22.95±2.47 .909(.833, .99)* .43(.29,.63)**
Religion Orthodox 67(54.0) 93(51.4) 1
Protestant 18(15.5) 29(16.0) 1.18(.56. 2.46)
Muslim 39(31.5) 59 (32.6) 1.09(.66, 1.79)
Origin Urban 49(39.5) 33(18.2) 1
Rural 75(60.5) 148(81.8) 2.93(1.74,4.93)* 1.27(1.04, 1.86)**
Filed Public 10(8.1) 9(5.0) 1
Medicine 23(18.5) 20(11.0) .85(.30, 2.35)
Pharmacy 22(17.7) 53(29.3) .82(.38,1.76)
Nurse 14(11.3) 23(12.7) 2.27(1.14, 4.52)
Laboratory 22(17.7) 41(22.7) 1.55(.68, 3.51)
Midwife 10(8.1) 9(5.0) 1.76(.87, 3.55)
Year of stay (μ±SD) 2.94±1.22 2.86±1.23 .95(.79, 1.14)
Chronic Yes 7(5.6) 15(8.3) 1
No 117(94.4) 166(91.7) .66(.56, 1.67)
Yes 103(83.1) 168(92.8) 1 1
No 21(16.9) 13(7.2) .38(.18, .79)* .07(.01, .71)**
Knowledge status about COVID 19 infection transmission, risk factors, and control behavior
Knowledge (μ±SD) 21.40±5.25 24.68±1.39 1.30(1.19, 1.41)* 1.45(1.14, 1.85) **
HBM
Susceptibility (μ±SD) 4.00±2.22 6.70±2.90 1.47(1.32, 1.63)* 1.70(1.15, 2.51)**
Severity (μ±SD) 4.64±2.89 6.83±2.14 1.37(1.25, 1.50)* 1.26(1.01, 1.57) **
Benefit (μ±SD) 8.20±2.09 9.81±2.13 1.43(1.27, 1.60)* .58(.38, .88)**
Barriers (μ±SD) 13.87±5.33 15.30±5.17 1.05(1.00, 1.09)* 1.10(.97, 1.26)
Cues to action (μ±SD) 3.26±.93 2.87±.81 .60(.46, .79)* .63(.35, 1.16)
Theory of planned behavior
Attitude (μ±SD) 18.75±5.28 9.36±3.75 .56(.49, .62)* .46(.35, .62)**
Subjective norm 3.70±1.39 3.78±1.09 1.06(.87, 1.27)
Behavioral control 2.5±0.88 2.39±0.81 1.04(.79, 1.37)
Regret 3.11±1.19 3.02±1.08 .93(.76, 1.14)
5C psychological antecedents
Confidence (μ±SD) 8.05±2.51 10.06±2.44 1.28(1.16, 1.41)* 1.93(1.24, 2.99)**
Constraints (μ±SD) 2.89±1.27 2.71±1.27 .89(.75, 1.07)
Complacency (μ±SD) 10.05±1.11 7.24±2.22 .89(.75, 1.07)
Calculation (μ±SD) 12.20±1.09 9.98±.73 .46(.38, .54)
Responsibility (μ±SD) 3.70±1.45 8.16±1.53 -

Discussion

According to this study, 40.7% with 95% CI (35.1,46.4) medical students were unwilling to recive COVID 19 vaccine., this finding is consistent with a similar study in Uganda [11, 25], but higher than a similar study in Egypt and Kazakhstan [9, 10, 26]. There is also another study that reports higher proportions like china, India [26], and Israel [21, 2729].

The discrepancy could be explained by the fact that the majority of prior studies were carried out in times of emergency, which might have had an impact on the vast majority of the study participants. As with earlier trials, refusal was motivated by concern over negative consequences as well as doubts about its efficacy [17].

The odds of unwillingness to accept COVID 19 vaccine is 1.45 times higher among medical university students who have higher k knowledge about COVID 19 transmission, risk factors, and preventive behavior.Tthis finding is in line with a similar research report [20, 21]. Because, having the knowledge about the transmission, risk factors, and preventive behavior of COVID 19 infection helps medical student to make appropriate deccession regarding COVID 19 vaccination.

In addition to this, the odds of unwillingness accept COVID 19 vaccine in the studied institution is increased by the three variables in the HBM. Accordingly perceived susceptibility to COVID 19 infection increased 1.70, perceived severity of COVID 19 infection increased 1.26, and perceived benefit of COVID 19 vaccine increased .58 times the odds of non-willingness to receive COVID 19 vaccine; while perceived barriers of COVID 19 vaccine were notassociated with unwillingness accept COVID 19 vaccine. This was comparable to prior research, with the exception that in the previous study, all components in the HBM predicted unwillingness to get COVID 19 vaccine, [12, 20, 30]. However in the current study, the perceive barrier did not demonstrate statistical significance association with medical student unwillingness accept COVID 19 vaccine. This, discripancey my tell that medical students believe in the studied area with respect to the possible short term and long term side effects of the COVID-19 vaccination did not influenced their status unwilling to accept COVID 19 vaccine. Also, from the variables under Theory of planned behavior only positive attitude toward the COVID 19 vaccine decreased the odds of unwillingness to recive COVID 19 vaccineby 54% [30, 31].

Finaly, from the variables under 5C psychological antecedents only Confidence is predicted unwillingness of medical student to accept COVID 19 vaccine; that is lack of confidence on safness, effectiveness of COVID 19 vaccines and lack of confidence on public authorities decissin in the best interest of the community increased the odds of unwillingness to accept COVID 19 vaccine 1.93 times among those medical student who lack confidence on COVID 19 vaccine safness and effectiveness. However, three of the 5C psychological antecedents namly Constraints, Complacency Calculation and Responsibility did not significantly predicted medical student unwillingness to accept COVID 19 vaccine. This finding is supported by study finding that studied COVID 19 vaccine hesitancy using HBM, TPB and 5C psychological antecedents except that in this research constraint did not predicted decision making COVID 19 vaccine [23].

Strengths and limitation

Although the study’s cross-sectional design limits the construction of a causal pathway, it was conducted when the vaccine was accessible, which is an optimal and suggested time to study vaccination reluctance.

Conclusion

In this study, 40.7% of medical students were not willing to receive the COVID 19 vaccine. And also increasing age, rural origion, perceived susceptibility, the severity of COVID 19 infection and perceived benefit of COVID 19 vaccine, positive attitude about COVID 19 vaccine, and confidence in the safety and efficacy of COVID 19 vaccine were predictors of non-willingness to receive COVID 19 vaccine. Therefore, the programmer and planner recommended focusing on theoretical constructs to improve vaccine acceptance of medical student.

Supporting information

S1 Questionnaire

(DOCX)

S1 Data

(SAV)

Acknowledgments

We would like to acknowledge our data collectors and study participant of this study.

List of abreviation

AOR

Adjusted Odds Ratio

CI

Confidence Interval

HBM

Health Believe Model: SWE South West Ethiopia

TPB

Theory of planned behavior

WHO

World Health Organization

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.WHO. tuberculosis fact sheet 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis. [Google Scholar]
  • 2.CDC. Basic TB Facts 2021. Available from: https://www.cdc.gov/tb/topic/basics/default.htm. [Google Scholar]
  • 3.Ashok N, Krishnamurthy K, Singh K, Rahman S, Majumder MAA. High COVID-19 Vaccine Hesitancy Among Healthcare Workers: Should Such a Trend Require Closer Attention by Policymakers? Cureus. 2021. Sep;13(9):e17990. doi: 10.7759/cureus.17990 . Pubmed Central PMCID: 8519358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.WHO. REPORT OF THE SAGE WORKING GROUP ON VACCINE HESITANCY01 October 2014. [Google Scholar]
  • 5.Tam CC, Qiao S, Li X. Factors associated with decision making on COVID-19 vaccine acceptance among college students in South Carolina. Psychology, health & medicine. 2021. Sep 23:1–12. doi: 10.1080/13548506.2021.1983185 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sharma M, Davis RE, Wilkerson AH. COVID-19 Vaccine Acceptance among College Students: A Theory-Based Analysis. International journal of environmental research and public health. 2021. Apr 27;18(9). doi: 10.3390/ijerph18094617 . Pubmed Central PMCID: 8123652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Altulaihi BA, Alharbi KG, Alaboodi TA, Alkanhal HM, Alobaid MM, Aldraimly MA. Factors and Determinants for Uptake of COVID-19 Vaccine in a Medical University in Riyadh, Saudi Arabia. Cureus. 2021. Sep;13(9):e17768. doi: 10.7759/cureus.17768 . Pubmed Central PMCID: 8494158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lim JS, Au Yong TPT, Boon CS, Boon IS. COVID-19 Vaccine Prioritisation for Medical Students: The Forgotten Cohort? Clinical oncology. 2021. Aug;33(8):e359. doi: 10.1016/j.clon.2021.02.013 . Pubmed Central PMCID: 7923859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bolatov AK, Seisembekov TZ, Askarova AZ, Pavalkis D. Barriers to COVID-19 vaccination among medical students in Kazakhstan: development, validation, and use of a new COVID-19 Vaccine Hesitancy Scale. Human vaccines & immunotherapeutics. 2021. Oct 6:1–11. doi: 10.1080/21645515.2021.1982280 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Jain J, Saurabh S, Kumar P, Verma MK, Goel AD, Gupta MK, et al. COVID-19 vaccine hesitancy among medical students in India. Epidemiology and infection. 2021. May 20;149:e132. doi: 10.1017/S0950268821001205 . Pubmed Central PMCID: 8185413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Saied SM, Saied EM, Kabbash IA, Abdo SAE. Vaccine hesitancy: Beliefs and barriers associated with COVID-19 vaccination among Egyptian medical students. Journal of medical virology. 2021. Jul;93(7):4280–91. doi: 10.1002/jmv.26910 . Pubmed Central PMCID: 8013865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Qiao S, Tam CC, Li X. Risk Exposures, Risk Perceptions, Negative Attitudes Toward General Vaccination, and COVID-19 Vaccine Acceptance Among College Students in south Carolina. American journal of health promotion: AJHP. 2021. Jun 24:8901171211028407. doi: 10.1177/08901171211028407 . [DOI] [PubMed] [Google Scholar]
  • 13.Belsti Y, Gela YY, Akalu Y, Dagnew B, Getnet M, Abdu Seid M, et al. Willingness of Ethiopian Population to Receive COVID-19 Vaccine. Journal of multidisciplinary healthcare. 2021;14:1233–43. doi: 10.2147/JMDH.S312637 . Pubmed Central PMCID: 8169050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zewude B, Habtegiorgis T. Willingness to Take COVID-19 Vaccine Among People Most at Risk of Exposure in Southern Ethiopia. Pragmatic and observational research. 2021;12:37–47. doi: 10.2147/POR.S313991 . Pubmed Central PMCID: 8166351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sadaqat W, Habib S, Tauseef A, Akhtar S, Hayat M, Shujaat SA, et al. Determination of COVID-19 Vaccine Hesitancy Among University Students. Cureus. 2021. Aug;13(8):e17283. doi: 10.7759/cureus.17283 . Pubmed Central PMCID: 8448273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kanyike AM, Olum R, Kajjimu J, Ojilong D, Akech GM, Nassozi DR, et al. Acceptance of the coronavirus disease-2019 vaccine among medical students in Uganda. Tropical medicine and health. 2021. May 13;49(1):37. doi: 10.1186/s41182-021-00331-1 . Pubmed Central PMCID: 8116637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Akarsu B, Canbay Ozdemir D, Ayhan Baser D, Aksoy H, Fidanci I, Cankurtaran M. While studies on COVID-19 vaccine is ongoing, the public’s thoughts and attitudes to the future COVID-19 vaccine. International journal of clinical practice. 2021. Apr;75(4):e13891. doi: 10.1111/ijcp.13891 . Pubmed Central PMCID: 7883065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Almalki MJ, Alotaibi AA, Alabdali SH, Zaalah AA, Maghfuri MW, Qirati NH, et al. Acceptability of the COVID-19 Vaccine and Its Determinants among University Students in Saudi Arabia: A Cross-Sectional Study. Vaccines. 2021. Aug 25;9(9). doi: 10.3390/vaccines9090943 . Pubmed Central PMCID: 8473185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Bou Hamdan M, Singh S, Polavarapu M, Jordan TR, Melhem NM. COVID-19 Vaccine Hesitancy among University Students in Lebanon. Epidemiology and infection. 2021. Nov 2:1–32. doi: 10.1017/S0950268821002314 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Nguyen VT, Nguyen MQ, Le NT, Nguyen TNH, Huynh G. Predictors of Intention to Get a COVID-19 Vaccine of Health Science Students: A Cross-Sectional Study. Risk management and healthcare policy. 2021;14:4023–30. doi: 10.2147/RMHP.S328665 . Pubmed Central PMCID: 8478496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Le An P, Nguyen HTN, Nguyen DD, Vo LY, Huynh G. The intention to get a COVID-19 vaccine among the students of health science in Vietnam. Human vaccines & immunotherapeutics. 2021. Oct 8:1–6. doi: 10.1080/21645515.2021.1981726 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Mahmud I, Kabir R, Rahman MA, Alradie-Mohamed A, Vinnakota D, Al-Mohaimeed A. The Health Belief Model Predicts Intention to Receive the COVID-19 Vaccine in Saudi Arabia: Results from a Cross-Sectional Survey. Vaccines. 2021. Aug 5;9(8). doi: 10.3390/vaccines9080864 . Pubmed Central PMCID: 8402432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hossain MB, Alam MZ, Islam MS, Sultan S, Faysal MM, Rima S, et al. Health Belief Model, Theory of Planned Behavior, or Psychological Antecedents: What Predicts COVID-19 Vaccine Hesitancy Better Among the Bangladeshi Adults? Frontiers in public health. 2021;9:711066. doi: 10.3389/fpubh.2021.711066 . Pubmed Central PMCID: 8418098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ahmed MH, Kanfe SG, Jarso MH. Intention to receive vaccine against COVID-19 and associated factors among health professionals working at public hospitals in resource limited settings. PloS one. 2021;16(7):e0254391. doi: 10.1371/journal.pone.0254391 . Pubmed Central PMCID: 8274862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kelekar AK, Lucia VC, Afonso NM, Mascarenhas AK. COVID-19 vaccine acceptance and hesitancy among dental and medical students. Journal of the American Dental Association. 2021. Aug;152(8):596–603. doi: 10.1016/j.adaj.2021.03.006 . Pubmed Central PMCID: 7997309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lucia VC, Kelekar A, Afonso NM. COVID-19 vaccine hesitancy among medical students. Journal of public health. 2021. Sep 22;43(3):445–9. doi: 10.1093/pubmed/fdaa230 . Pubmed Central PMCID: 7799040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Gao X, Li H, He W, Zeng W. COVID-19 Vaccine Hesitancy Among Medical Students: The Next COVID-19 Challenge in Wuhan, China. Disaster medicine and public health preparedness. 2021. Sep 9:1–6. doi: 10.1017/dmp.2021.291 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Kaur A, Kaur G, Kashyap A, Singh G, Singh Sandhu H, Khilji I, et al. Attitude and acceptance of Covid-19 vaccine amongst medical and dental fraternity—a questionnaire survey. Roczniki Panstwowego Zakladu Higieny. 2021;72(2):185–91. doi: 10.32394/rpzh.2021.0162 . [DOI] [PubMed] [Google Scholar]
  • 29.Rosental H, Shmueli L. Integrating Health Behavior Theories to Predict COVID-19 Vaccine Acceptance: Differences between Medical Students and Nursing Students. Vaccines. 2021. Jul 13;9(7). doi: 10.3390/vaccines9070783 . Pubmed Central PMCID: 8310115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Thaker J, Ganchoudhuri S. The Role of Attitudes, Norms, and Efficacy on Shifting COVID-19 Vaccine Intentions: A Longitudinal Study of COVID-19 Vaccination Intentions in New Zealand. Vaccines. 2021. Oct 4;9(10). doi: 10.3390/vaccines9101132 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Abebe H, Shitu S, Mose A. Understanding of COVID-19 Vaccine Knowledge, Attitude, Acceptance, and Determinates of COVID-19 Vaccine Acceptance Among Adult Population in Ethiopia. Infection and drug resistance. 2021;14:2015–25. doi: 10.2147/IDR.S312116 . Pubmed Central PMCID: 8179743. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Subish Palaian

23 May 2022

PONE-D-21-36100

Predictors of Unwillingness to receive COVID -19 vaccines among Ethiopian Medical student

PLOS ONE

Dear Dr. Getachew,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript in one month. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Subish Palaian

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

A clean copy of the edited manuscript (uploaded as the new *manuscript* file).

3. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

4. Thank you for stating the following financial disclosure:

“no fund”

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. Please amend your authorship list in your manuscript file to include author Eyob Bekele.

6. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Additional Editor Comments:

I request authors to revise the manuscript based on reviewers' comments. In addition, the Ethical approval details should be mentioned in the manuscript. The abstract should be formatted as per the journal style. The questionnaire validation should be discussed in detail. The discussion section appears weak and should be rewritten to make stronger arguments and conclusions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The statistical method used is correct. Adequate analyses have been performed. The manuscript is unintelligible in some places. The authors have made all data underlying the findings in their manuscript available if needed.

Reviewer #2: The title is Ok.

ABSTRACTS

There are so many typographical errors . Example: "In this study 145(40%) of medical student were not willing to receive COVID-19 vaccination. And also age of student .43(.29,.63), Knowledge status about COVID 19 infection transmission, risk factors and control behavior 1.45(1.14, 1.85), perceived susceptibility, perceived severity perceived benefit, positive attitude and confidence on safety and efficacy of the vaccine were predictors of non-willingness to receive COVID 19 vaccine."

How can age be .43?

There are so many unnecessary use of upper case. Example: 'Therefore, this study assessed Predictors of Unwillingness to receive COVID -19 vaccines among Ethiopian Medical student. "

INTRODUCTION

The authors should beef up the justification for the study

RESULTS

The authors should include a flow chart showing the participants flow in the study.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Review comments.docx

PLoS One. 2022 Nov 2;17(11):e0276857. doi: 10.1371/journal.pone.0276857.r002

Author response to Decision Letter 0


23 Jun 2022

Journal requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

Response: Editors of journals, We've acknowledged the suggestion and updated the manuscript to comply with PLOS ONE's style guidelines. That is the Author, affiliation formatting guide line, which is used to change the title page, and the manuscript body formatting guide line, which is used to change the manuscript body. While doing so, the above-mentioned URL came in handy, and we'd like to thank the journal team for providing these rules.

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Response: We have completely copyedited the manuscript for language use, spelling, and grammar, and we appreciate you for your patience.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

A clean copy of the edited manuscript (uploaded as the new *manuscript* file

3. Please provide additional details regarding participant consent.

In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information

Response: Thank you, editors, for your advice with the ethical statement. We utilized written informed consent. As a result, informed written consent was acquired directly from participants, all of whom were above the age of 18. we have included in the manuscript as follow “This study was conducted in harmony with the Declaration of Helsinki. Mizan Tepi University Research Ethics Review Committee approved it. All participant were assured the autonomy to participate or not, the a written informed consent was sought from each participant.”

4. Thank you for stating the following financial disclosure:

“no fund”

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: The authors received no specific funding for this work

5. Please amend your authorship list in your manuscript file to include author Eyob Bekele.

Response: Thank you, dear editors, for recommending that the authorship list be updated by adding author Eyob Bekele to the text file.

6. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

Response: thank you dear editors, we have included the ethical statement in the method section, as follow “This study was conducted in harmony with the Declaration of Helsinki. Mizan Tepi University Research Ethics Review Committee approved it. All participant were assured the autonomy to participate or not, the a written informed consent was sought from each participant.”

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: Thank you, dear editor; we've added captions to the Supporting Information files at the end of the paper, and we've updated any in-text citations to match.

Additional Editor Comments:

I request authors to revise the manuscript based on reviewers' comments. In addition, the Ethical approval details should be mentioned in the manuscript. The abstract should be formatted as per the journal style. The questionnaire validation should be discussed in detail. The discussion section appears weak and should be rewritten to make stronger arguments and conclusions.

[Note: HTML markup is below. Please do not edit.]

Response: Thank you very much, editor. The majority of the comments from reviewers and editors were accepted. We've also made the necessary changes to the document. The ethical approval statement is included in the manuscript, the abstract part is organized according to journal style, and the validity of the questionnaire was also explored in detail. Finally, we attempted to modify the section on discussion.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

Response: Dear Reviewer, thank you for your time and consideration. the data or supporting material supplied as part of the paper

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

________________________________________

Response: Dear Reviewer, we have updated the English language to meet normal English requirements.

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The statistical method used is correct. Adequate analyses have been performed. The manuscript is unintelligible in some places. The authors have made all data underlying the findings in their manuscript available if needed.

Response: Regards, Reviewer We've modified the English language to suit Standard English criteria, making it more understandable.

Reviewer #2: The title is Ok.

ABSTRACTS

There are so many typographical errors . Example: "In this study 145(40%) of medical student were not willing to receive COVID-19 vaccination. And also age of student .43(.29,.63), Knowledge status about COVID 19 infection transmission, risk factors and control behavior 1.45(1.14, 1.85), perceived susceptibility, perceived severity perceived benefit, positive attitude and confidence on safety and efficacy of the vaccine were predictors of non-willingness to receive COVID 19 vaccine."

How can age be .43?

There are so many unnecessary use of upper case. Example: 'Therefore, this study assessed Predictors of Unwillingness to receive COVID -19 vaccines among Ethiopian Medical student. "

Response: thank you dear reviewer we would like to apologize for the typographical errors, we have tried to correct it. We have also corrected unnecessary use of upper cases.

INTRODUCTION

the authors should beef up the justification for the study

Response: we have tried to add more justification for the study

RESULTS

The authors should include a flow chart showing the participants flow in the study.

Response :

________________________________________

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Dragan Pamucar

10 Aug 2022

PONE-D-21-36100R1Predictors of Unwillingness to receive COVID -19 vaccines among Ethiopian Medical studentPLOS ONE

Dear Dr. Getachew,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 24 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Dragan Pamucar

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: a. The grammatical errors and English language correction is to be done.

b. The discussion still seems incomplete.

Reviewer #2: The authors should remove the ampersand in 'Study area & period"

The authors should endeavor to add flow chart showing the participants flow.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: George Eleje

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Nov 2;17(11):e0276857. doi: 10.1371/journal.pone.0276857.r004

Author response to Decision Letter 1


30 Sep 2022

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s)

PONE-D-21-36100R1

Predictors of Unwillingness to receive COVID -19 vaccines among Ethiopian Medical student

Editors comment

PLOS ONE

Dear Dr. Getachew,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 24 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Author response: Hello reviewer I appreciate the advice and criticism you provided. When the first academic editor left, my colleague and I were concerned. However, now that you are here and have provided such insightful scientific feedback, we are pleased to have you and your help enhance this work as a whole. Additionally, we are ready to consider all suggestions or comments.

Editors comment

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

Author response: Regarding financial disclosure, as the amount is about equal to our yearly gross income, we have requested publication support.

Editors comment

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

Author response: Thank you, Editor; we followed the instructions to submit figure files; we found the PACE to be extremely fascinating; we appreciate your advice.

Editors comment

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

Author response: Thank you, Editor; but I don’t think this is applicable for this manuscript.

We look forward to receiving your revised manuscript.

Kind regards,

Dragan Pamucar

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Author response: My dear reviewer, While searching through our reference list, we were unable to locate a retracted article. Inappropriately mentioned articles have been amended and removed, too.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

________________________________________

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

________________________________________

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

________________________________________

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

________________________________________

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: a. The grammatical errors and English language correction is to be done.

Author response: Thank you, reviewer. We have removed any grammatical errors, corrected them, and copy edited the English language

b. The discussion still seems incomplete.

Author response: Reviewer, I appreciate your time. The discussion section has been widened and elaborated where necessary.

Reviewer #2: The authors should remove the ampersand in 'Study area & period"

The authors should endeavor to add flow chart showing the participants flow.

Author response: Please accept our apologies for putting the ampersand in the incorrect place. Thank you. Regarding putting the flow chart we added the flow chart.

________________________________________

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Author response:

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: George Eleje

________________________________________

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Author response: Thank you, Editor; we followed the instructions to submit figure files; we found the PACE to be extremely fascinating; we appreciate your advice.

________________________________________

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Remove my information/details). Please contact the publication office if you have any questions.

ReplyForward

Reviewer comment from the action link "View Attachments"

Summary: The study topic is relevant. The design is overall good but needs some clarifications in certain sections.

Overall impression: Some doubts have to be cleared.

Author Response: Thank you dear reviewer, you have given us constructive comment we have included your comment in the revised manuscript to clarify certain section.

Major issues:

Reviewer comment: The semantic error and lack of abbreviations, mostly in the result and discussion sections have made the manuscript difficult to comprehend.

Author Response: Thank you dear reviewer, we apologize for not included list of abbreviation, now in the revised version of the manuscript list of abbreviation was included.

Reviewer comment: Method section, subsection “Sample Size determination and sampling technique”: Please mention the formula.

Author Response: Thank you dear reviewer, we have mention the formula as single population proportion formula and we have included the formula.

Reviewer comment :Is the questionnaire validated and pre-tested?

Author Response: yes the questionnaire is pretested and validated

Minor issues:

Reviewer comment: Result section, 349 line number: Is it percentage and number in the bracket?

Author Response: Thank you dear reviewer, comment accepted the number in the bracket it is percentage and corrected accordingly 207(67.9%).

Reviewer comment: Please elaborate the discussion by adding some contrasting findings to that of other studies.

Author Response: Thank you dear reviewer, we have accepted your comment and elaborated the discussion by adding some contrasting finding.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Dragan Pamucar

17 Oct 2022

Predictors of unwillingness to receive COVID -19 vaccines among Ethiopian Medical student

PONE-D-21-36100R2

Dear Dr. Getachew,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Dragan Pamucar

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The authors have addressed the comments raised. The study is now acceptable. COVID-19 remains a topic interests in all concerned.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Acceptance letter

Dragan Pamucar

21 Oct 2022

PONE-D-21-36100R2

Predictors of unwillingness to receive COVID -19 Vaccines among Ethiopian Medical students

Dear Dr. Getachew:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Dragan Pamucar

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Questionnaire

    (DOCX)

    S1 Data

    (SAV)

    Attachment

    Submitted filename: Review comments.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES